meeting. This free to use advanced prototype demonstration system (http://accumetra.com/accumetra-solutions) allows radiologists and physicists to upload a CT scan of three rolls of scotch tape and emails back a quantitative report translating fundamental performance characteristcs of the scanner into clinically meaningful performance indicators. Radiologists can now determine whether their scanning protocols provide sufficient quality for the clinical task at hand. Reports currently contain quantitative information on small lung nodule detection and volume measurement performance. This new approach to quantitatively monitoring and verifying the quality of a CT scan in radiological task performance terms enables many additional uses including comparing two different protocols or scanners, verifying whether CT scanning quality is sufficient for specific clinical studies, and monitoring that the optimal balance of radiation dose and image quality is being attained. Accumetra’s image quality assessment platform can also be extended to additional clinical applications including detection and measurement of coronary calcifications, chronic obstructive pulmonary disease (COPD), and orthopedic studies. When released for clinical use, calibrated phantoms will be used in place of demonstration tape to ensure that high quality reports are generated in the clinical setting. Accumetra is a key technical contributor to the Radiological Society of North America’s Quantitative Imaging Biomarkers Alliance (QIBA) and is demonstrating this free service to assist the radiological community in developing and setting new standards for quantitative imaging. Press Contact All press enquiries, including interview requests, product reviews, images and quotes should be directed to info@accumetra.com. About Accumetra, LLC Accumetra is an imaging technology and services company committed to advancing the science of image-based decision making in the medical domain. Accumetra provides advanced computational imaging tools and consultation services for healthcare institutions and clinical study sponsors.